Neurosense Therapeutics Ltd
NRSN
查看詳細走勢圖
0.940USD
+0.070+8.03%
收盤 02/06, 16:00（美東）報價延遲15分鐘
23.12M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+8.03%
5天
+2.16%
1月
+0.20%
6月
-25.40%
今年開始到現在
+22.22%
1年
-18.97%
查看詳細走勢圖
TradingKey 股票評分
由於缺少必要的數據，暫時無法對該公司進行評分
Neurosense Therapeutics Ltd新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Neurosense Therapeutics Ltd簡介
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
公司代碼NRSN
公司Neurosense Therapeutics Ltd
CEOBen-Noon (Alon)
網址https://www.neurosense-tx.com/
相關品種
+3.63%
+3.17%
+0.93%
+1.99%
+1.78%
+1.53%
-0.96%
+4.49%
+2.10%
+10.00%
+2.72%
+4.07%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%熱門品種
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70716.100
-89.070 (-0.13%)
282.580
+22.390 (+8.61%)
2081.070
-21.020 (-1.00%)
411.110
+13.900 (+3.50%)
5020.480
+67.500 (+1.36%)
62.863
-0.440 (-0.69%)
1.182
-0.000 (-0.02%)
156.853
-0.245 (-0.16%)
